Posted inHematology-Oncology news
Slow but Steady: t(11;14) Myeloma Shows Superior Outcomes Despite Delayed MRD Negativity with Quadruplet Therapy
t(11;14) multiple myeloma exhibits slower MRD clearance but superior PFS with quadruplet therapy and MRD-adapted management, challenging conventional response kinetics paradigms.
